Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METADEP: Cocktail Phenotypic Approach in Depression
NCT02438072Unknown
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of omeprazole, caffeine, flurbiprofen, dextromethorphan, midazolam and 2 more in major depressive disorder (MDD). Primary endpoints: CYP1A2 activity, CYP2B6 activity and 5 more. Status: unknown.
02
Drugs
omeprazolecaffeineflurbiprofendextromethorphanmidazolam
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02438072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438072.